NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines

This study shows that vandetanib might be one of useful treatment strategies for CRC patient with NCOA4-RET fusion. Therefore, inhibition of the RET kinase is a promising targeted therapy for cancer patients whose tumors harbor a RET rearrangement.

Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Sun Young Kim, Seiyoon Oh Oh, Kyung Kim, Jeeyun Lee, SoYoung Kang, Kyoung-Mee Kim, WooYong Lee, Seung Tae Kim, Dohyun Nam Nam Tags: Research Paper Source Type: research